{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:45:55Z","timestamp":1777556755013,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite high response rates to initial therapy, most patients with mantle cell lymphoma (MCL) experience relapsed or refractory (R\/R) disease. Here, we report the efficacy, safety, and pharmacokinetics of the Phase 2, single-arm M20-075 study (NCT04477486) of ibrutinib and venetoclax combination therapy in Japanese patients with R\/R MCL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients received 560\u00a0mg ibrutinib and 400\u00a0mg venetoclax (after a 5-week ramp-up from 20\u00a0mg) once daily for up to 104\u00a0weeks. Primary endpoint was complete response (CR) rate by independent review committee (IRC). Secondary endpoints included overall response rate (ORR), duration of response (DOR), undetectable minimal residual disease (uMRD) rate, progression-free survival (PFS), overall survival (OS), safety including dose-limiting toxicity (DLT) assessment in the first six patients, and pharmacokinetic parameters. Full analysis set (FAS) comprised all treated patients. Per protocol set (PPS) excluded treated patients with non-evaluable disease at baseline by IRC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirteen patients were treated (FAS <jats:italic>n<\/jats:italic>\u2009=\u200913; PPS, <jats:italic>n<\/jats:italic>\u2009=\u200912). Median age was 71\u00a0years, patients had a median of two prior treatments. After a median follow-up of 9.6\u00a0months, IRC-assessed CR rate and ORR were both 83% (PPS). All six MRD-evaluable patients had uMRD. Median DOR, PFS, and OS were unreached. The most common Grade\u2009\u2265\u20093 treatment-emergent adverse event (TEAE) was neutropenia (23%); 1 patient discontinued due to squamous cell carcinoma of the lung. No DLTs, tumor lysis syndrome, or deaths related to TEAEs were observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Ibrutinib plus venetoclax exhibited high response rates and a well-tolerated safety profile in Japanese patients with R\/R MCL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10147-023-02443-6","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T05:02:45Z","timestamp":1703826165000},"page":"232-240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed\/refractory mantle cell lymphoma"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8361-9973","authenticated-orcid":false,"given":"Hideki","family":"Goto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Terui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumiko","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Soshin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiewei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Badawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"key":"2443_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3960\/jslrt.20056","volume":"61","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Suzumiya J, Takizawa J et al (2021) Real world treatment practices for mantle cell lymphoma in japan: an observational database research study (CLIMBER-DBR). J Clin Exp Hematop 61:135\u2013144","journal-title":"J Clin Exp Hematop"},{"key":"2443_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/jha2.311","volume":"3","author":"T Alnassfan","year":"2022","unstructured":"Alnassfan T, Cox-Pridmore MJ, Taktak A et al (2022) Mantle cell lymphoma treatment options for elderly\/unfit patients: a systematic review. EJHaem 3:276\u2013290","journal-title":"EJHaem"},{"key":"2443_CR3","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks K (2018) Update on mantle cell lymphoma. Blood 132:1647\u20131656","journal-title":"Blood"},{"key":"2443_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1200\/EDBK_175448","volume":"37","author":"JB Cohen","year":"2017","unstructured":"Cohen JB, Zain JM, Kahl BS (2017) Current approaches to mantle cell lymphoma: diagnosis, prognosis, and therapies. Am Soc Clin Oncol Educ Book 37:512\u2013525","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2443_CR5","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1182\/bloodadvances.2022007247","volume":"6","author":"M Narkhede","year":"2022","unstructured":"Narkhede M, Goyal G, Shea L et al (2022) Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv 6:4122\u20134131","journal-title":"Blood Adv"},{"key":"2443_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood.2021013326","volume":"139","author":"TA Eyre","year":"2022","unstructured":"Eyre TA, Cheah CY, Wang ML (2022) Therapeutic options for relapsed\/refractory mantle cell lymphoma. Blood 139:666\u2013677","journal-title":"Blood"},{"key":"2443_CR7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M et al (2016) Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 387:770\u2013778","journal-title":"Lancet"},{"key":"2443_CR8","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","volume":"32","author":"S Rule","year":"2018","unstructured":"Rule S, Jurczak W, Jerkeman M et al (2018) Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 32:1799\u20131803","journal-title":"Leukemia"},{"key":"2443_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3960\/jslrt.19006","volume":"59","author":"D Maruyama","year":"2019","unstructured":"Maruyama D, Nagai H, Fukuhara N et al (2019) Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed\/refractory mantle cell lymphoma. J Clin Exp Hematop 59:98\u2013100","journal-title":"J Clin Exp Hematop"},{"key":"2443_CR10","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1111\/cas.13076","volume":"107","author":"D Maruyama","year":"2016","unstructured":"Maruyama D, Nagai H, Fukuhara N et al (2016) Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. Cancer Sci 107:1785\u20131790","journal-title":"Cancer Sci"},{"key":"2443_CR11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF et al (2017) Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol 35:826\u2013833","journal-title":"J Clin Oncol"},{"issue":"2","key":"2443_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/leu.2013.249","volume":"28","author":"M Axelrod","year":"2014","unstructured":"Axelrod M, Ou Z, Brett LK et al (2014) Combinatorial drug screening identifies synergistic co-targeting of Bruton\u2019s tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia 28(2):407\u2013410","journal-title":"Leukemia"},{"key":"2443_CR13","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C et al (2018) Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med 378:1211\u20131223","journal-title":"N Engl J Med"},{"key":"2443_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13045-021-01188-x","volume":"14","author":"M Wang","year":"2021","unstructured":"Wang M, Ramchandren R, Chen R et al (2021) Concurrent ibrutinib plus venetoclax in relapsed\/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol 14:179","journal-title":"J Hematol Oncol"},{"key":"2443_CR15","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMra0904569","volume":"364","author":"SC Howard","year":"2011","unstructured":"Howard SC, Jones DP, Pui CH (2011) The tumor lysis syndrome. N Engl J Med 364:1844\u20131854","journal-title":"N Engl J Med"},{"key":"2443_CR16","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068","journal-title":"J Clin Oncol"},{"key":"2443_CR17","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","volume":"27","author":"MS Davids","year":"2021","unstructured":"Davids MS, Roberts AW, Kenkre VP et al (2021) Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase i, first-in-human study. Clin Cancer Res 27:4690\u20134695","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2443_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1182\/blood.V124.21.509.509","volume":"124","author":"CA Portell","year":"2014","unstructured":"Portell CA, Axelrod M, Brett LK et al (2014) Synergistic cytotoxicity of ibrutinib and the bcl2 antagonist, abt-199(gdc-0199) in mantle cell lymphoma (mcl) and chronic lymphocytic leukemia (cll): molecular analysis reveals mechanisms of target interactions. Blood 124(21):509","journal-title":"Blood"},{"key":"2443_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/bjh.13149","volume":"168","author":"X Zhao","year":"2015","unstructured":"Zhao X, Bodo J, Sun D et al (2015) Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol 168:765\u2013768","journal-title":"Br J Haematol"},{"key":"2443_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12185-020-03024-3","volume":"113","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Yamamoto K, Kato K et al (2021) Phase 1\/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Int J Hematol 113:370\u2013380","journal-title":"Int J Hematol"},{"key":"2443_CR21","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T et al (2021) Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol 39:3853\u20133865","journal-title":"J Clin Oncol"},{"key":"2443_CR22","doi-asserted-by":"crossref","unstructured":"Doki N, Toyosaki M, Shiratori S et al. (2021) An open-label, single-arm, multicenter study of ibrutinib in japanese patients with steroid-dependent\/refractory chronic graft-versus-host disease. Transplant Cell Ther 27:867 e861\u2013867 e869","DOI":"10.1016\/j.jtct.2021.05.019"},{"key":"2443_CR23","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","volume":"24","author":"MS Davids","year":"2018","unstructured":"Davids MS, Hallek M, Wierda W et al (2018) Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia. Clin Cancer Res 24:4371\u20134379","journal-title":"Clin Cancer Res"},{"key":"2443_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM et al (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374:311\u2013322","journal-title":"N Engl J Med"},{"key":"2443_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/bjh.15791","volume":"186","author":"WG Wierda","year":"2019","unstructured":"Wierda WG, Byrd JC, O\u2019Brien S et al (2019) Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol 186:184\u2013188","journal-title":"Br J Haematol"},{"key":"2443_CR26","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, Walter HS, Iyengar S et al (2019) Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica 104:e68\u2013e71","journal-title":"Haematologica"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02443-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02443-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02443-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T03:06:39Z","timestamp":1706151999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02443-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2443"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02443-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]},"assertion":[{"value":"13 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Venetoclax is being developed in collaboration between AbbVie and Genentech. Ibrutinib is being developed in collaboration between AbbVie and Janssen Research & Development, LLC. The study sponsor funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data, and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Daniel Roybal, PhD, of Bio Connections, LLC, funded by AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Hideki Goto reports lecture fees earned from Kyowa Kirin. Satoshi Ito reports research funding from AbbVie, Amgen, Insight, Novartis, and Zenyaku-Kogyo. Masahiro Kizaki has nothing to declare. Masaki Yamaguchi has nothing to declare. Noriko Fukuhara reports research funding from AbbVie, Bayer, Celgene, Chordia Therapeutics, Chugai, Genmab, Incyte, Kyowa-Kirin, LOXO Oncology, and Takeda. Koji Kato reports research funding from AbbVie, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Janssen, Kyowa Kirin, Novartis, and Takeda. Toko Saito has nothing to declare. Yasuhito Terui reports lecture fees earned from AbbVie, Celgene, Chugai, Eisai, Janssen, Ono, and Symbio and a certain contribution from Eisai. Sumiko Okubo reports employment with and research funding from AbbVie and may hold stock options or other ownership in AbbVie. Tomomi Soshin reports her and her husband\u2019s employment with AbbVie and may hold stock options or other ownership in AbbVie. Jiewei Zeng reports employment with AbbVie and may hold stock options or other ownership in AbbVie. Hideyuki Honda reports employment with AbbVie and may hold stock options or other ownership in AbbVie. Mohamed Badawi reports employment with and research funding from AbbVie and may hold stock options or other ownership in AbbVie. Jeremy A. Ross reports employment with and research funding from AbbVie and may hold stock options or other ownership in AbbVie. Koji Izutsu reports advisory board and honoraria fees from AbbVie.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}